Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.

摘要: Objectives: Effective chemotherapy with the least toxicity is important for patients inoperable or advanced hepatocellular carcinoma. Single use of pegylated liposomal doxorubicin has been reported to be safe and effective varying treatment response. The authors evaluate its activity in combination capecitabine gemcitabine as salvage therapy these patients. Methods: At first, intravenous administration 30 mg/m 2 60 minutes on day 1, oral 1500 mg twice daily from 1 14 every 4 weeks (trial A) was conducted. Following unfavorable results, a second trial B) performed subsequent same schedule, but 1000 over 8, followed by 2-week rest. Results: Both trials showed no objective response, stable disease each trial. In A, control rate all evaluative (complete response + partial disease) progression-free survival responders were 20%, 164 days 240 versus 22%, 75 73 B. median overall A B 161 84 respectively. Generally, toxicities well managed without toxic death. Conclusion: Pegylated doxorubicin-based not Further systemic carcinoma warranted.